James Metz, MD
OncoLink Associate Editor
Ultima Vez Modificado: 1 de noviembre del 1999
Presenter: Michael L. Haas, MD
Affiliation: University of Maryland
Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer.
From 1993-1998 62 patients received weekly carboplatin/taxol chemotherapy with radiation therapy. Radiation was delivered to a total dose of 70.2 Gy in 1.8 Gy fractions to the primary site. The majority of patients had oropharyngeal cancer.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.